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Introduction
Invasive breast cancers (IBCs) can be divided into two
subtypes based on whether or not the tumor cells express
estrogen receptor alpha (ER) in their nuclei. The ER status
is important because, when circulating estrogen binds ER,
it stimulates cell division and tumor growth [1]. Many
strategies have been developed over the years to inhibit
this estrogen-induced mitogenic pathway. Numerous
previous studies have shown that these so-called
hormonal therapies significantly prolong life, although they
rarely cure patients with ER-positive IBCs, where the
mitogenic pathway is intact, but that they are ineffective in
ER-negative disease, where the pathway is inactive [1].
More recent studies suggest that hormonal therapies can
also delay or prevent the development of IBC in high-risk
women, primarily by reducing ER-positive disease,
although longer follow-up may show a benefit in ER-
negative disease as well [2].
Despite their usefulness, current hormonal therapies are
still imperfect and improving them will depend on gaining
a better understanding of the cellular and molecular
mechanisms responsible for determining whether ER is
expressed and how it is regulated during the evolution of
IBCs. There are probably several mechanisms and,
although none are understood at a fundamental level,
several clinical, pathological, and experimental
observations provide food for thought for future research
in this area [3].
ER and growth in precursors of breast cancer
All IBCs appear to evolve over long periods of time from
premalignant breast lesions, which in turn appear to
evolve from normal epithelial cells lining terminal duct
lobular units (TDLUs) [4]. Understanding ER and growth
in IBCs may benefit from, or even depend on, a similar
understanding of their precursors, especially normal cells.
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Abstract
Current hormonal therapies have benefited millions of patients with breast cancer. Their success,
however, is often temporary and limited to a subset of patients whose tumors express estrogen
receptor alpha (ER). The therapies are entirely ineffective in ER-negative disease. Recent studies
suggest that there are many biological pathways and alterations involved in determining whether ER is
expressed and how it is regulated during breast cancer evolution. Improving hormonal therapies, in
addition to perfecting current strategies, will also target these newly discovered pathways and
alterations, and others yet to be found. The present commentary will briefly highlight a few important
observations and unanswered questions regarding ER status and growth regulation during breast
cancer evolution, which hopefully will help to stimulate new thinking and progress in this important area
of medial research.
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Since estrogen, presumably mediated through ER,
appears necessary to stimulate mitosis and populate the
TDLU with normal epithelial cells, one might postulate that
all epithelial cells or their ancestors must express ER at
some time during their lifecycle. Immunohistochemical
studies of normal breast tissue from adult women,
however, show that while nearly all TDLUs contain ER-
positive cells, on average only about 30% of the cells are
positive at one point in time (Fig. 1a), and they are almost
never dividing [5]. In fact, dividing cells account for less
than 5% of the population overall, and they are almost
always ER-negative [5]. The largest population in normal
breast consists of ER-negative nondividing cells. This mix
is hard to explain if they are stable populations unless, for
example, they came from an ER-positive or otherwise
estrogen-responsive stem cell and are differentiated in
diverse directions afterwards. Alternatively, perhaps ER
expression and cell division occur sequentially in the same
cells, with intervening periods of receptor negativity and
quiescent cell cycling, which would be difficult to detect
with static assays such as immunohistochemistry. The
answer is unknown but important because estrogen,
mediated through ER, directly or indirectly stimulates cell
division, and only dividing cells are able to propagate the
genetic alterations responsible for the evolution of
premalignant lesions to breast cancer.
Although the precise nature of premalignant evolution is
controversial, especially the earliest stages, most models
agree that IBCs evolve in a nonobligatory fashion through
an increasingly abnormal series of hyperplasias, atypical
hyperplasias, and noninvasive or in situ carcinomas [4].
Certain lesions are widely acknowledged to have
significant premalignant potential, including atypical ductal
hyperplasia (ADH) and atypical lobular hyperplasia, and
their more advanced counterparts ductal carcinoma in situ
(DCIS) and lobular carcinoma in situ, respectively [4].
Unlike normal TDLUs in which ER is expressed in a
minority of cells, most of these precursors express high
levels of ER in nearly all cells (Fig. 1b,c,e,f) [4]. The major
exception is DCIS, which show an evenly distributed
continuum of ER expression from very high to very low
levels, including a subset (~25%) that is entirely ER-
negative (Fig. 1d) [4]. Also unlike normal TDLUs, in which
dividing cells are nearly always ER-negative, the majority
of dividing cells in most precursors are ER-positive [6].
Thus, two abnormalities highly characteristic of the
majority of premalignant lesions, especially early lesions,
are a large increase in ER-positive cells overall, and in ER-
positive dividing cells, with perhaps the latter representing
an expanded stem cell or progenitor cell population. All
premalignant lesions contain at least a few ER-negative
epithelial cells, however, which could also play a
progenitor cell role in the evolution of some IBCs.
ER and growth in breast cancers
Compared with the majority of premalignant lesions
except DCIS, IBCs show much more diversity regarding
the proportion of lesions containing ER-positive cells, the
proportion of ER-positive cells in each lesion, and the
proportion of dividing cells that are ER-positive [5]. About
75% of IBCs contain ER-positive cells, but the proportion
varies on a continuum ranging from less than 1% to nearly
Figure 1
Examples illustrating typical levels of estrogen receptor alpha (ER) expression in normal and premalignant breast epithelial cells (dark nuclei,
ER-positive as assessed by immunohistochemistry). On average, (a) normal premenopausal terminal duct lobular units contain about 30%
ER-positive cells. In contrast, nearly all cells express very high levels of ER in the majority of premalignant breast lesions, including (b) atypical
ductal hyperplasia, (e) atypical lobular hyperplasia, (f) and lobular carcinoma in situ. Ductal carcinoma in situ is an exception, showing a continuum
of ER expression ranging from (c) very high levels characteristic of histologically lower-grade lesions to very low levels characteristic of
higher-grade lesions, including a substantial subset (~25%) that is entirely ER-negative (d).
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100% (Fig. 2) [7]. In ER-positive IBCs, the proportion of
dividing cells that are ER positive also varies from less
than 1% to nearly 100%, but the average is more than
100-fold above that of normal cells [5]. The remaining
25% of IBCs contain no ER-expressing cells, so all the
dividing cells in this group are ER-negative.
The clinical definition of an ER-positive IBC is one with a
statistically significant chance of responding favorably and
safely to hormonal therapy. This simple definition is
satisfied by a biologically diverse group of tumors showing
a wide range of ER expression from very low to very high.
Although there is a gradient of clinical response directly
correlated with ER content, the gradient is skewed such
that tumors containing even a very small proportion of ER-
positive cells (e.g. between 1% and 10%) respond far
better than ER-negative tumors, and nearly as well as
tumors with high levels of ER (Fig. 3) [7]. Assuming that
this surprising clinical response is based on inhibiting
estrogen-stimulated growth mediated through functional
ER, it raises several questions regarding the nature of stem
or progenitor cells that could produce and sustain such
heterogeneous populations in the first place, yet still
respond in a similar manner to hormonal therapy. Whether
it is just the ER-positive cells that are capable of dividing, or
whether ER expression and growth are cyclical phenomena
in the same cells, or both, or whether entirely different
mechanisms are operating are all unknown at this time.
A significant (~30%) proportion of ER-positive IBCs do
not benefit from current hormonal therapy at all, which is
hard to explain without invoking other mechanisms that
augment or entirely bypass the classical estrogen-
stimulated mitogenic pathway. Recent laboratory studies
are confirming and shedding light on such alternate
pathways. For example, contrary to the prevailing notion
Figure 3
Kaplan–Meyer curves illustrating the surprising skewed relationship
between estrogen receptor alpha (ER) status (immunohistochemistry
[IHC] scores) and clinical outcome (disease-free survival [DFS]) in
patients (n = 777) with invasive breast cancer treated with adjuvant
tamoxifen therapy (reproduced with permission) [7]. Tumors with as
few as 1–10% ER-positive cells (IHC score = 3) respond far better
than ER-negative tumors (IHC score = 0 and 2 corresponding to none
and < 1% ER-positive cells, respectively), and nearly as well as tumors
with much higher ER content (IHC score = 4–8 corresponding to
> 10% to 100% ER-positive cells). The observation that tumors with a
low proportion of ER-positive cells respond almost as well as those
with a very high proportion raises important questions about the nature
of stem cells that could produce and sustain such biologically diverse
but clinically similar populations.
Figure 2
Examples illustrating the wide range of estrogen receptor alpha (ER) expression characteristic of invasive breast cancers (IBCs) (dark nuclei, ER-
positive as assessed by immunohistochemistry). (a) A substantial (~25%) subset of IBCs does not contain any ER-expressing cells. The majority
(~75%), however, do contain ER-expressing cells, but the proportion varies on an evenly distributed continuum ranging from (b, c) very low, to (d,
e) intermediate, to (f) very high.
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that ER is entirely in the nucleus, it was recently learned
that a small amount of functional ER may also reside in the
outer cell membrane, especially in tumor cells
overexpressing certain growth factor receptors, such as
epidermal growth factor receptor (EGFR) and HER2,
which are also in the outer membrane. Tamoxifen, one of
the most commonly used types of hormonal therapy,
appears to function as a beneficial antagonist on nuclear
ER, but as a harmful agonist on membrane ER [8].
Activated membrane ER can then activate adjacent EGFR
and/or HER2, which may then stimulate tumor growth.
Theoretically, other types of hormonal therapies such as
the aromatase inhibitors, which greatly reduce
endogenous estrogen, might remain beneficial in this
setting. There are almost certainly additional undiscovered
mechanisms explaining why some ER-positive IBCs fail to
benefit from hormonal therapy at all, or respond initially
only to become resistant later, which is unfortunately very
common.
ER-negative IBCs are a more obvious departure from
normal breast epithelial cells than ER-positive IBCs in the
sense that they contain no ER expressing cells yet still
manage to survive and grow. In fact, ER-negative IBCs are
often histologically high-grade, rapidly proliferating tumors.
Most ER-negative IBCs probably evolved from ER-
negative DCIS, which both represent about 25% of their
respective categories and resemble each other in many
other ways. However, this just refocuses the question on
the origin of ER-negative DCIS. In this regard, most DCIS
probably evolved from ADH, in which nearly all cells are
highly ER-positive. The DCIS that develop directly from
ADH are thought to be predominately histologically low-
grade/ER-positive lesions. While often overlooked, there is
considerable evidence suggesting that higher-grade/ER-
negative DCIS may evolve from lower-grade DCIS as they
accumulate additional genetic/epigenetic alterations that
influence cell morphology, arguing that even high-
grade/ER-negative DCIS evolve from ADH, although
indirectly. However, at least a few ER-negative cells are
present in all types of premalignant lesions, including
ADH, and they could be involved as progenitor cells in the
development of ER-negative DCIS. For example, perhaps
these rare cells represent a stable ER-negative population
normally supported by estrogen-induced paracrine factors
from adjacent ER-positive cells, which can become
independent of this support, achieve a growth advantage,
and progress to ER-negative breast cancer. Consistent
with this, investigators commonly derive ‘normal’ cell lines
from primary human mammary epithelial cells that,
surprisingly, are nearly always ER-negative. Human
mammary epithelial cells show gene expression patterns
similar to so-called basal IBCs, which are also ER-
negative [9], leading to the speculation that they may
represent a stem cell population for receptor-negative
breast cancer [10].
On the whole, however, the majority of available evidence
suggests that most ER-negative DCIS or IBCs arise from
ER-positive precursors or cells that stop expressing the
receptor. For example, prolonged exposure to estrogen,
especially during adolescence, is among the strongest risk
factors for eventually developing IBC, presumably by
allowing genetic alterations to accumulate in ER-positive
cells continually stimulated to proliferate [11]. Of the IBCs
that eventually develop, about 25% are ER-negative,
consistent with the idea that some ER-positive precursors
stopped expressing the receptor after being initiated. The
incidence of ER-positive tumors is significantly higher in
small than large IBCs, also supporting the notion that ER
expression is turned off in some tumors as they progress
and enlarge [7,12]. Reducing estrogen by oophorectomy
in high-risk carriers of BRCA1 mutations greatly reduces
the overall incidence of IBC, including ER-negative
tumors, which indirectly argues that ER-dependent or
otherwise estrogen-dependent pathways give rise to ER-
negative disease [13]. Similarly, although tamoxifen in the
NSABP-P1 Breast Cancer Prevention Trial primarily
reduced the incidence of ER-positive IBCs in the short
term [2], longer follow-up has more recently shown a
reduction in the incidence of premalignant disease [14],
which could eventually translate to a reduction in ER-
negative IBCs that might evolve from them.
There are other more concrete examples providing further
evidence that ER-negative breast cancers might evolve
from ER-positive precursors or cells. For instance, nearly
all IBCs are associated with a noninvasive component
(DCIS and/or lobular carcinoma in situ), probably
representing residual precursors. In a small (~5%)
proportion of ER-negative IBCs, the in situ component is
ER-positive, often strongly so (Fig. 4). Another case in
point is that 10–20% of metastases associated with ER-
positive primary IBCs are entirely ER-negative [3,15].
Examples supporting the opposite (the evolution of ER-
positive DCIS or IBCs from ER-negative precursors or
cells) are almost unheard of, further implying that ER-
positive is the predominant precursor phenotype. These
examples are associated with relatively advanced stages
of breast cancer evolution (DCIS or beyond) with
prominent genetic instability and diversity, which could
result in the loss of ER expression. Surprisingly, however,
there is very little evidence that mutations or chromosomal
imbalances play a significant role in the loss of ER,
suggesting that other regulatory or epigenetic
mechanisms secondarily downregulate gene and/or
protein expression.
It was noted many years ago that IBCs overexpressing
certain membrane growth factor receptors (EGFR, HER2,
and fibroblast growth factor receptor) were often ER-
negative [16–18], suggesting that this subset of tumors
selected alternate mechanisms of growth bypassing the
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classical estrogen-induced mitogenic pathway. However,
although laboratory studies transfecting and over-
expressing these receptors in ER-positive breast cancer
cell lines inhibited their responsiveness to estrogen
[19–21], including estrogen-induced growth, they
continued to express ER, suggesting that these pathways
may only be partially involved in the evolution of ER-
negative breast cancer. Experiments overexpressing the
raf proto-oncogene, which transduces peptide-induced
mitogenic signaling through the mitogen-activated protein
kinase pathway, causes ER-positive breast cancer cell
lines to become ER-negative and insensitive to estrogen
[22]. Similar studies upregulating c-Jun expression, a
component of the AP-1 transcription factor pathway,
results in loss of ER and responsiveness to estrogen in
ER-positive cells [23]. More recent studies have also
shown that exposing ER-positive breast cancer cell lines to
low oxygen levels, a common condition in vivo during
breast cancer evolution, especially in certain lesions such
as high-grade DCIS, can result in loss of ER through
protein degradation, possibly mediated by upregulation of
the transcription factor hypoxia-induced factor 1 alpha [24].
Among the most interesting mechanisms that may be
playing a role in the evolution of ER-negative breast
cancers are those normally involved in reversibly down-
regulating gene transcription by altering chromosomal
structure, such as DNA methylation and histone acetyl-
ation [25]. Clinical studies have shown that methylation of
the ER gene is much more prominent in ER-negative than
ER-positive IBCs, and possibly responsible for turning off
ER expression. Related laboratory studies have shown
that inhibitors of methylation and histone deacetylation in
ER-negative breast cancer cell lines can reactivate the
expression of functional ER, generating hope that similar
strategies can be used in patients with ER-negative IBC,
converting their tumors to ER-positive, which may then be
responsive to conventional hormonal therapies.
Conclusions
There are three general goals for better hormonal
therapies in breast cancer, including improving therapies
for ER-positive disease, finding therapies for ER-negative
disease and, especially, broadening therapies for
prevention to include ER-negative disease. Achieving
these goals will depend on gaining a better understanding
of the mechanisms determining whether ER is expressed
and how it is regulated during the evolution of normal cells
to premalignant lesions to breast cancers. Many critical
questions remain unanswered regarding the existence,
identity, and ER status of stem cells that may be central to
this evolution. The majority of available evidence suggests
that most breast cancers, including ER-negative breast
cancers, arise from ER-positive or otherwise estrogen-
responsive progenitor cells through potentially reversible
epigenetic mechanisms. Other possibilities remain,
however, such as the existence of a small, stable ER-
negative population with stem cell properties for a subset
of ER-negative disease. On the bright side, each newly
revealed mechanism represents a potential target for more
effective therapies.
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